ライフサイエンスコーパス: liver biopsy

1 easurements of the liver (within 6 months of liver biopsy).

2 s predicted to reduce harms from unnecessary liver biopsy.

3 The diagnosis of NASH currently requires a liver biopsy.

4 eferred for HVPG measurement or transjugular liver biopsy.

5 false-positive testing and the frequency of liver biopsy.

6 nderwent a detailed metabolic assessment and liver biopsy.

7 respectively, for all subjects who underwent liver biopsy.

8 diatric CF liver disease (CFLD) validated by liver biopsy.

9 f having NAFLD who underwent contemporaneous liver biopsy.

10 iver procurement underwent a FibroScan and a liver biopsy.

11 turnover; oral glucose tolerance test; and a liver biopsy.

12 rty-one of the children with NAFLD underwent liver biopsy.

13 s a means for predicting disease severity on liver biopsy.

14 ts with abnormal results were considered for liver biopsy.

15 tohepatitis, and 73.5% had fibrosis on index liver biopsy.

16 via histologic analysis in all patients with liver biopsy.

17 ,644 patients with T1DM, 57 (1.2%) underwent liver biopsy.

18 bset underwent cardiac catheterizations with liver biopsy.

19 most diverse histopathologic observations in liver biopsy.

20 liver ultrasound, and 24 of these underwent liver biopsy.

21 s conducted in 77 patients who had NAFLD and liver biopsy.

22 s and anthropometric measures at the time of liver biopsy.

23 probes, and FibroTest within 1 month before liver biopsy.

24 with or without alcoholic hepatitis without liver biopsy.

25 ients consecutively examined by percutaneous liver biopsy.

26 outcome was the degree of bile duct loss on liver biopsy.

27 erwent bariatric surgery and intra-operative liver biopsy.

28 n the cohort except 1 were managed without a liver biopsy.

29 or 3-5 weeks prior to a clinically indicated liver biopsy.

30 rwent clinical and laboratory evaluation and liver biopsy.

31 ho met criteria, 56 had TE, whereas 34 had a liver biopsy.

32 The results were compared with those from liver biopsy.

33 nd had a higher interobserver agreement than liver biopsy.

34 in a cohort of NAFLD patients who underwent liver biopsy.

35 M probe), and ARFI within two weeks prior to liver biopsy.

36 d with progression from steatosis to NASH in liver biopsies.

37 Histology was performed on liver biopsies.

38 esence of diffuse vascular C4d expression on liver biopsies.

39 T3 (n=15) or TG (n=17) using yearly protocol liver biopsies.

40 Forty patients underwent liver biopsies.

41 ts were prospectively included and performed liver biopsies.

42 similar to that previously reported in human liver biopsies.

43 eatment responses were correlated in patient liver biopsies.

44 sion localized to CK7(+) DR and LPCs in CFLD liver biopsies.

45 Thirty patients had F0/F1 fibrosis stage at liver biopsy (10 with NASH), and 27 patients had signifi

46 is, or liver disease, except for the rate of liver biopsy (10.9% versus 1.8% [p = 0.013] in males; 9.

47 spective study, all patients who underwent a liver biopsy 1984-2009 at the National University Hospit

48 ts with NAFLD without diabetes and who had a liver biopsy (29 NAFLD-NO and 15 NAFLD-Ob) and 20 CTs wi

49 In patients with liver biopsy, 88.2% had recurrent NAFLD, whereas 41.2% h

50 According to the degree of liver fibrosis at liver biopsy, 88.5%-96.8% of patients were correctly cla

51 were rejected for HBcAb+ (33%), HCV+ (18%), liver biopsy (9%), HBsAg+ (6%), neoplastic (6%), or infe

52 negative CHB patients who had indication for liver biopsy according to The American Association for t

53 nance imaging and 39 required an unnecessary liver biopsy according to the recall policy.

54 ave elastography (Supersonic Aixplorer), and liver biopsy after an overnight fast.

55 nts who underwent SWE before their scheduled liver biopsy (age range, 18-76 years; mean age, 49 years

56 omparable cohort of NAFLD patients underwent liver biopsy, an oral glucose tolerance test with minima

57 parable cohort of NAFLD patients underwent a liver biopsy, an oral-glucose-tolerance test with minima

58 ts (56.7% female) who underwent MRE, TE, and liver biopsy analysis (using the histologic scoring syst

59 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through

60 l study, 67 children with CFLD had dual-pass liver biopsies and 104 age- and sex-matched CF children

61 e of HCV RNA and ISG mRNA detection in human liver biopsies and applied it to study the interaction o

62 We collected frozen liver biopsies and clinical data from patients with biop

63 nificantly up-regulated both in HCV-positive liver biopsies and in HCV-infected primary human hepatoc

64 characterized the expression of hCH25H using liver biopsies and primary human hepatocytes.

65 Liver biopsies and serum samples from 113 morbidly obese

66 Liver biopsies and serum samples were obtained at the be

67 is (stage 2 or lower) was observed in 18% of liver biopsies and stage 3 was observed in 0.7%, but cir

68 During 2001-2010, 22.3% had a liver biopsy and 37.9% were hospitalized.

69 r 72 weeks of obeticholic acid or placebo by liver biopsy and MRI (scanners from different manufactur

70 y recognition of HLH and B. henselae through liver biopsy and serological tests led to the patient's

71 Ten patients did not accept liver biopsy and six patients had contraindications for

72 ients with fibrosis stage>/=F2; testing with liver biopsy and treating patients with >/=F2; treat non

73 events occurred (pain after a post-treatment liver biopsy and vertigo), both unrelated to study drugs

74 Premortem diagnoses, liver biopsies, and FIB-4 scores (a noninvasive measure

75 nce with infected primary human hepatocytes, liver biopsies, and hepatoma cell lines.

76 ating global transcriptomic data, from human liver biopsies, and metabolic flux data, measured across

77 cases of massive hemobilia in children after liver biopsy are a rarity in the scientific literature b

78 tions of massive hemobilia in children after liver biopsy are a rarity in the scientific literature b

79 Using liver biopsy as a starting point, we analyzed the develo

80 egative CHB patients that had indication for liver biopsy as recommended by AASLD and APASL guideline

81 dictive models of liver retrievability using liver biopsy as the gold standard have led to the follow

82 collagen content and lobular inflammation on liver biopsy, as well as improvements in serum biomarker

83 standardized research visit: history, exam, liver biopsy assessment (using the nonalcoholic steatohe

84 ut concurrent liver diseases, who had repeat liver biopsies at eight U.S.-based medical centers, were

85 Forty-five patients who underwent liver biopsy at a single tertiary care center were prosp

86 liver cancer and genetic studies of a human liver biopsy atlas with the aim of identifying putative

87 is histological feature is usually missed by liver biopsy because of limited sampling, and MiVI is co

88 alcoholic fatty liver disease still requires liver biopsy, biomarkers to detect advanced fibrosis are

89 management can be avoided while the need for liver biopsies can be reduced.

90 In the liver biopsy cohort, 188 subjects (13%) were carriers of

91 fected Huh7.5 cells and HCV-infected patient liver biopsies compared to controls.

92 expression is significantly elevated in HCV+ liver biopsies compared to hepatitis B virus (HBV+) and

93 in subjects with severe steatosis (>/=66% at liver biopsy) compared to those without (F0-F1 6.9 versu

94 r suspected infection or relapse followed by liver biopsy comprised the study group.

95 We propose that the need for liver biopsy could be reduced if abnormalities in at lea

96 In the Liver Biopsy Cross-Sectional Cohort, a total of 1149 ind

97 ents) and 1149 European individuals from the Liver Biopsy Cross-Sectional Cohort.

98 cted clinical, serologic, (1)H-MRS PDFF, and liver biopsy data from 94 adult patients with increased

99 A liver biopsy demonstrated centrilobular cholestasis and

100 In liver biopsies, disorders of the cholangiocytes primary

101 health systems in the United States who had liver biopsies during 2001-2012.

102 demonstrated in all 5 patients who received liver biopsies during the study.

103 Eligible patients underwent liver biopsy during consideration for interferon-alpha b

104 Among individuals undergoing liver biopsy, fibrosis stage correlated with increasing

105 Six patients on therapy underwent a liver biopsy for flow cytometric analysis.

106 tests have been proposed as alternatives to liver biopsy for identifying fibrosis or cirrhosis.

107 mples were obtained from patients undergoing liver biopsy for suspected NAFLD or NASH, or during live

108 as evaluated in 1,201 patients who underwent liver biopsy for suspected NASH; 427 were evaluated for

109 sulin-treated type 2 diabetes (T2IN) who had liver biopsy formed two comparative cohorts.

110 e cAMR score distribution on 1-year protocol liver biopsy found that 41% had a score less than 13; 27

111 and Switzerland (validation cohort 1) and in liver biopsies from 20 patients (9 received corticostero

112 esponse [SVR]; n=1 relapse) and unpaired EOT liver biopsies from 25 patients (n=17 SVR; n=8 relapse).

113 Findings were validated using liver biopsies from 48 consecutive patients with severe

114 Liver biopsies from 63 C282Y homozygous patients were as

115 using paired pre- and end-of-treatment (EOT) liver biopsies from 8 patients (n=7 sustained virologic

116 hCYP7A1 transcription, was also confirmed in liver biopsies from HBV-infected patients.

117 ific target genes was also observed in human liver biopsies from HCC patients compared to healthy pat

118 FVIII protein in B lymphoblastoid cells and liver biopsies from individuals with the intron 22 inver

119 e time of Kasai portoenterostomy, along with liver biopsies from infants without BA (controls).

120 characterize gene expression in percutaneous liver biopsies from low-risk, "mild" NAFLD patients (fib

121 Moreover, E2F1 expression was increased in liver biopsies from obese, glucose-intolerant humans com

122 after chronic ethanol feeding, as well as in liver biopsies from patients with alcoholic liver diseas

123 Liver biopsies from patients with ALD showed a robust in

124 Increased phospho-MLKL staining in liver biopsies from patients with autoimmune hepatitis s

125 Index liver biopsies from patients with autoimmune-like hepati

126 different experimental systems as well as in liver biopsies from patients with chronic HCV.

127 in hepatocytes and hepatic stellate cells in liver biopsies from patients with fibrosis, cirrhosis, a

128 We obtained transjugular liver biopsies from patients with hepatitis C virus-asso

129 This mediator was also detected in liver biopsies from patients with NASH and its degree of

130 Liver biopsies from PSC patients were collected from sev

131 ired pretreatment and end of treatment (EOT) liver biopsies from SVR patients showed that viral clear

132 We identified patients who have had liver biopsy from a computerized database (DIAMOND; Hico

133 IHC staining of a liver biopsy from a patient with FLUX-induced liver inju

134 ian age: 7.2 years; range, 0.2-27) underwent liver biopsy, gastroscopy, abdominal ultrasound, and lab

135 d liraglutide and underwent end-of-treatment liver biopsy had resolution of definite non-alcoholic st

136 ced disease is challenging and may require a liver biopsy, highlighting the urgent need for reliable,

137 first 50 consecutive patients who underwent liver biopsy in 2008 were included.

138 y fistula which developed incidentally after liver biopsy in a 10-year-old boy with chronic hepatitis

139 resonance (MR) spectroscopy with results of liver biopsy in a cohort of adult patients suspected of

140 hat FibroSURE may be a useful substitute for liver biopsy in chronic HBV infection.

141 on-invasive models and methods to substitute liver biopsy in chronic hepatitis B (CHB) patients were

142 d FibroTest results, as well as the need for liver biopsy in this cohort.

143 s as a test replacement strategy (to replace liver biopsy) in making key decisions in the management

144 In unpaired EOT liver biopsies, intrahepatic expression of fatty acid me

145 identify liver disease in such patients, but liver biopsy is necessary to definitively identify those

146 Liver biopsy is the gold standard method to assess nonal

147 Liver biopsy is the reference standard for the detection

148 noninvasive tests (NITs) as alternatives to liver biopsy is unknown.

149 In situations where liver biopsy is unsuitable or unavailable the white cell

150 We compared the prognostic value of liver biopsy (LB) and FIB-4 index in patients with human

151 ometry of intrahepatic T cells isolated from liver biopsy led to the targeted treatment with anti-tum

152 All patients received a liver biopsy, lifestyle assessment, blood tests, and QOL

153 sed by paired pretreatment and posttreatment liver biopsies, magnetic resonance elastography, magneti

154 Liver biopsy may be considered in elderly patients and t

155 Liver biopsy may contribute to diagnostic accuracy, but

156 In liver biopsies, miR-21 and miR-221 displayed a reciproca

157 zed trial underwent a paired evaluation with liver biopsy, MRI-PDFF, and MRS-PDFF at the baseline and

158 tially expressed serum miRNA with concordant liver biopsy mRNA demonstrates interaction between molec

159 A large study of percutaneous liver biopsies (n = 2740) in HCV-infected patients with

160 ase over a 10-year period that had undergone liver biopsies (n = 363) were scored for the presence of

161 imization before and at clinically indicated liver biopsy (n = 119).

162 Patients undergoing liver biopsy (n = 69) provided fasting blood, fresh tiss

163 re associated with liver disease severity on liver biopsy (n = 96), but CXCL10, interleukin 6 (IL-6),

164 tion associated with invasive tests, such as liver biopsy, noninvasive imaging modalities for liver f

165 ither group are willing to under go a repeat liver biopsy (NS).

166 Initial screening studies of human liver biopsies obtained during hepatic transplantation d

167 ematically evaluated histological changes in liver biopsies obtained from 249 patients with suspected

168 uced signaling and gene regulation in paired liver biopsies obtained prior to treatment and during th

169 was performed on both pre- and posttreatment liver biopsies of 59 PIVENS patients randomized to VitE

170 ymes of glutamine metabolism in vitro and in liver biopsies of chronic HCV patients.

171 er RNA (mRNA) levels of HCV entry factors in liver biopsies of HCV patients infected with different g

172 The histopathologic findings of core liver biopsies of liver metastases identified by needle

173 mRNA expression of ISGs was higher in EOT liver biopsies of patients who achieved SVR than in pati

174 -lambda receptor chain (IFN-lambdaR1) in 122 liver biopsies of patients with CHC and 53 control sampl

175 The analysis of liver biopsies of patients with CHC revealed a strong as

176 a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver

177 ion was decreased and c-Jun was increased in liver biopsies of patients with steatosis and NASH compa

178 In liver biopsies of subjects with alcoholic or hepatitis B

179 their baseline fibrosis classified by either liver biopsy or liver stiffness measurement (LSM).

180 nfection diagnosis with cirrhosis-defined by liver biopsy or mean FIB-4 score >5.88-and time to onset

181 l cancer and were scheduled for percutaneous liver biopsy or thermal ablation were eligible for this

182 iver fibrosis was assessed histologically by liver biopsy or transient elastometry.

183 Overall, 435 liver biopsy pairs from 282 patients without cirrhosis w

184 Prerecovery liver biopsy (PLB) allows histological evaluation of the

185 Percutaneous liver biopsy (PLB) is the "gold standard" in the diagnos

186 tohepatitis was replicated in 44 independent liver biopsies (r = 0.47, P = 0.0013).

187 atic steatosis was observed between PDFF and liver biopsy (r = 0.82).

188 tuberculosis immune reconstitution syndrome; liver biopsy remains a useful diagnostic procedure in th

189 Liver biopsy remains critical for staging liver disease

190 Whereas liver biopsy remains the gold standard for staging of di

191 When comparing MR elastography results with liver biopsy results, the best cutoff for advanced fibro

192 aphic results as well as fibrosis stage from liver biopsy results.

193 Analysis of paired liver biopsies revealed altered expression of genes asso

194 Histopathological examinations of liver biopsies revealed mild, periportally accentuated i

195 Evaluation of liver biopsies revealed that pegIFN-alpha induces hundre

196 Archival liver biopsy samples from 43 HCV+ LT recipients were col

197 We obtained liver biopsy samples from 69 patients with chronic HCV i

198 We obtained fixed liver biopsy samples from 71 consecutive patients diagno

199 HCV replicon-harboring cells, as well as in liver biopsy samples from chronically HCV-infected patie

200 Ex vivo molecular MR imaging of liver biopsy samples from NASH and control patients conf

201 in cells dying of this pathway and in human liver biopsy samples from patients suffering from drug-i

202 Liver biopsy samples obtained from HBV-chronic individua

203 ngle cell laser capture microdissection from liver biopsy samples of patients chronically infected wi

204 Human liver biopsy samples showed the presence of the HCV-spec

205 profiles were compared between seven paired liver biopsy samples taken before and 6 months after suc

206 Eleven human liver biopsy samples underwent MPO-Gd-enhanced MR imagin

207 Liver biopsy samples were available for 1201 patients (9

208 Blood and liver biopsy samples were collected before treatment and

209 iRNA expression level was also measured from liver biopsy samples.

210 teatohepatitis (NASH) mouse models and human liver biopsy samples.

211 MPO activity in NAFLD mouse models and human liver biopsy samples.

212 n/ID1 mRNA expression in chronic HCV patient liver biopsy samples.

213 who underwent MRE, ARFI, and contemporaneous liver biopsies scored using the Nonalcoholic Steatohepat

214 te was characterized by immunostaining NAFLD liver biopsy sections (n = 33) for broad leukocyte subse

215 HCV isolate- and ISG mRNA-specific probes in liver biopsy sections from 18 CHC patients.

216 HCV-infected children who had more than one liver biopsy separated by over 1 year.

217 Referral to a specialist and a possible liver biopsy should be considered if persistent hypertra

218 The liver biopsy showed a higher prevalence of fibrosis (P =

219 in HeLa cells, and electron microscopy of a liver biopsy showed dilated organelles suggestive of the

220 Features of liver biopsies significantly associated with death or li

221 Using unstained liver biopsy slides from 56 children with NAFLD, we perf

222 Histologic analysis of liver biopsy specimens allows for grading and staging of

223 HCV-infected liver biopsy specimens also displayed lower expression l

224 While methods for cccDNA quantification from liver biopsy specimens and cell lines expressing the vir

225 on of the key gluconeogenic enzymes in human liver biopsy specimens and found that only hepatic pyruv

226 ailure to describe blinded interpretation of liver biopsy specimens and inadequate description of enr

227 th miRNA expression levels were lower in HCC liver biopsy specimens compared with normal liver RNA.

228 prospective study, we analyzed percutaneous liver biopsy specimens from 73 consecutive patients with

229 Thus, we analyzed serial liver biopsy specimens from adult liver recipients enrol

230 Liver biopsy specimens from chronically HCV-infected pat

231 andem mass spectrometry and analyzed BMP6 in liver biopsy specimens from patients by immunohistochemi

232 In liver biopsy specimens from patients with acute hepatiti

233 All liver biopsy specimens from patients with late relapse w

234 ted a lower level of C9 mRNA expression than liver biopsy specimens from unrelated disease or healthy

235 treatment and relapse serum specimens and in liver biopsy specimens obtained during SVR.

236 mRNA displayed a significant increase in the liver biopsy specimens of chronically HCV-infected patie

237 hat miRNA-122 (miR-122) is down-regulated in liver biopsy specimens of patients with ALF and in aceta

238 ver tissue from a rat model of NAFLD, and in liver biopsy specimens of patients with simple steatosis

239 Analysis of human liver biopsy specimens revealed a correlation of DPP4 ex

240 A lymphocytic infiltrate was seen on liver biopsy specimens taken from 2 subjects with transa

241 )H-MRS), instead of collecting and analyzing liver biopsy specimens to detect steatosis.

242 Liver biopsy specimens were analyzed by in situ hybridiz

243 Liver biopsy specimens were collected at baseline (n = 4

244 All liver biopsy specimens were retrieved from archives and

245 Liver biopsy specimens, usually collected via the transj

246 3 expression in hepatocytes and HCV-infected liver biopsy specimens.

247 stinguishing benign from malignant tissue in liver biopsy specimens.

248 ted by cytokeratin-7 immunohistochemistry in liver biopsies, staged for fibrosis, from 60 children wi

249 Liver biopsy still is regarded as the reference for diff

250 V-monoinfected patients who had a qualifying liver biopsy, the mean age at the time of biopsy was 50.

251 hepatitis (AH) often requires a transjugular liver biopsy (TJLB), a procedure that is not always read

252 Here we used HCV-infected cells and liver biopsies to study how HCV modulates the glutaminol

253 assess hepatic fat content and 11 underwent liver biopsy to assess the degree of disease severity.

254 changes for 52 weeks and underwent a second liver biopsy to confirm NASH resolution.

255 ohort, a total of 1149 individuals underwent liver biopsy to diagnose liver disease and disease sever

256 harts of deceased patients were reviewed for liver biopsy to evaluate for disease recurrence.

257 Time at risk was determined from the date of liver biopsy to the date of outcome or last follow-up ex

258 The latter were compared with liver biopsy transcriptomes from IA (n = 16) and IT (n =

259 Liver fibrosis was assessed by means of liver biopsy, transient elastography, and clinical cirrh

260 infection without cirrhosis (as assessed by liver biopsy, transient elastography, or serum markers).

261 Cirrhosis was identified by liver biopsy, ultrasound, endoscopic analysis, and bioch

262 This is the first liver biopsy-validated study of APRI and FIB-4 in pediat

263 and liver-related mortality of patients with liver biopsy verified fatty liver disease in a populatio

264 We also assessed whether liver biopsy versus follow-up with the same versus alter

265 Median time interval between MR imaging and liver biopsy was 14.5 days (range, 0-259 days).

266 sistent with the (1)H-MRS data, steatosis on liver biopsy was also significantly increased in patient

267 Liver biopsy was performed only if the confirmatory scan

268 A liver biopsy was performed to assess histology (grade/st

269 If NAFLD was suspected, a liver biopsy was proposed.

270 of 330 patients who underwent pretherapeutic liver biopsy, we analyzed the HCC incidence in relations

271 Pretransplant liver biopsies were analyzed by immunostaining and elect

272 Paired liver biopsies were available from 261 patients.

273 Intraoperative liver biopsies were categorized with NAFLD Activity Scor

274 Liver biopsies were collected 2 weeks after the last dos

275 Intraoperative core liver biopsies were collected from 165 subjects; 17 were

276 Liver biopsies were collected from 37 of the patients pr

277 Liver biopsies were collected when the study began and a

278 Liver biopsies were examined for the presence of fibrin,

279 V-infected patients who underwent at least 2 liver biopsies were included in this study.

280 Liver biopsies were performed 2 and 4 years off IS, and,

281 Liver biopsies were then collected and patients were ass

282 clinical and demographic data who underwent liver biopsy were analyzed and clinicopathologically ass

283 rom 1 month to 17.2 years old) who underwent liver biopsy were analyzed.

284 Ballooning and/or inflammation at liver biopsy were associated with increased plasma BCAAs

285 Results Steatosis grades at liver biopsy were distributed as follows: S0, five patie

286 iver transplantation, and had a protocolized liver biopsy were evaluated (n = 230).

287 273 consecutive patients (65% female) with a liver biopsy were included (age, 44 +/- 0.76 years; body

288 nts with chronic liver disease who underwent liver biopsy were prospectively enrolled from April 2010

289 orty patients with a clinical indication for liver biopsy were prospectively recruited for liver ECV

290 nts with chronic liver disease scheduled for liver biopsy were prospectively recruited from November

291 Consecutive NAFLD patients who underwent liver biopsy were prospectively recruited.

292 tive pediatric patients scheduled to undergo liver biopsy were studied with an ultrasonography-based

293 ssociated liver injury had bile duct loss on liver biopsy, which was moderate to severe (<50% of port

294 minotransferases and hepatic architecture in liver biopsies with simple steatosis.

295 agnosis of alcoholic fibrosis and cirrhosis; liver biopsy with Ishak score and collagen-proportionate

296 After transjugular liver biopsy with pressure measurements as part of the s

297 data, there were 142 patients who underwent liver biopsy within 1 year of MR elastography.

298 In 289 patients who underwent liver biopsy within 1 year of the MR elastography date,

299 Forty patients who had had a liver biopsy within the previous month were recruited.

300 Using both cutoffs, a liver biopsy would have been avoided in 229 (88%) of 261